This diagnostic image consists of two sagittal T2-weighted magnetic resonance imaging (MRI) scans of the female pelvic floor, comparing anatomy before (a) and after (b) treatment for stress urinary incontinence (SUI). The images focus on the mid-urethra and vaginal wall interface. Key anatomical landmarks are labeled: U1 represents the upper end of the urethra (vesicourethral boundary), U0 marks the lower end (urethral opening), and U0.5 indicates the midway point. In image (a), representing the baseline (T0), the anterior (Va) and posterior (Vp) vaginal walls measured at the level of U0.5 appear thinner with a combined thickness of approximately 8 mm. In image (b), representing the post-treatment state (T3), there is a visible increase in the combined thickness of the Va and Vp to approximately 12 mm, suggesting tissue remodeling or swelling. A red dotted box highlights the adipose tissue space and urethral morphology, which shifts from an elliptical shape in (a) to a more circular configuration in (b). The image illustrates the anatomical changes associated with laser therapy in the management of pelvic floor disorders.

This medical anatomical diagram illustrates the pathophysiology and treatment of stress urinary incontinence (SUI) through three coronal views of the human bladder and urethra (A, B, and C). Diagram A represents normal anatomy and function, showing a healthy bladder muscle, intact ureters, and a closed urethra supported by strong sphincter and pelvic floor muscles. Diagram B depicts the mechanism of stress urinary incontinence, where external 'stress' (indicated by downward arrows) causes involuntary urine leakage through a weakened urethral opening and compromised pelvic floor support. Diagram C demonstrates a therapeutic intervention using urethral bulking agents. It shows the injection of 'microspheres' into the periurethral tissues, which facilitates complete coaptation (closure) of the urethral lumen to prevent leakage. Key labels include the bladder muscle, ureters, urethra, sphincter muscles, and pelvic floor muscles. The illustration is designed for educational use in urology to explain urinary control mechanisms and the clinical application of polymeric microspheres as bulking agents.

Pelvic floor sonography images demonstrating the management of recurrent stress urinary incontinence using a combination of a Tension-free Vaginal Tape (TVT) and a bulking agent (Bulkamid). Image (a) is a sagittal view showing the bladder (B) and urethra (U) under straining. It reveals proximal urethral funneling (F) and a TVT positioned too distally, failing to provide support. Image (b) shows the same sagittal view following the injection of bulking agent depots (white arrows). The depots are positioned between the bladder neck and the TVT, effectively closing the urethral lumen during straining to restore continence. Image (c) provides an axial view of the urethra, illustrating four hypoechoic bulking agent depots (white arrows) arranged circularly around the urethral lumen to achieve coaptation. The echogenic TVT (yellow arrow) is visible in its relation to the stabilized urethral structure. These images illustrate the use of functional ultrasound to assess implant positioning and surgical outcomes in urogynecology.